A Non-interventional, Prospective, Observational Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2022 Results evaluating the effectiveness and safety of apremilast in bio-naive patients with moderate psoriasis, published in the Journal of the European Academy of Dermatology and Venereology
03 Dec 2021 Results assessing 52-week treatment cost per patient achieving >75% reduction in Psoriasis Area Severity Index and per patient attaining Dermatology Life Quality Index presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
01 Sep 2021 Interim results assessing efficacy and safety of apremilast in biologic-naive patients with moderate psoriasis published in the Journal of the European Academy of Dermatology and Venereology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com